sitagliptin phosphate (+) metformin hydrochloride

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

CompletedNCT00961857

Merck Sharp & Dohme LLCType 2 Diabetes

Start: 2005-12-01End: 2006-01-01Updated: 2019-11-13

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

CompletedNCT00961480

Merck Sharp & Dohme LLCType 2 Diabetes

Start: 2007-10-31End: 2007-11-30Updated: 2015-06-09

Phase 3

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

CompletedNCT00482729

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2007-06-19End: 2009-04-27Updated: 2017-06-09

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

CompletedNCT00532935

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2008-01-26End: 2009-10-23Updated: 2017-06-09

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

CompletedNCT00541450

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2008-01-15End: 2010-01-16Updated: 2017-05-12